|Bid||53.20 x 1300|
|Ask||62.00 x 800|
|Day's Range||54.10 - 54.74|
|52 Week Range||52.30 - 65.20|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||0.97|
|Expense Ratio (net)||0.14%|
Vanguard is easy to recommend as a destination for investors aiming to simplify their financial lives by investing with a single firm. Morningstar's analyst team gives the firm an A rating for stewardship, owing to its strong corporate culture and ultra-low-cost products. It also fields the largest number of Morningstar Medalist funds of any fund firm.
For real estate mutual funds and exchange-traded funds (ETFs), the 2018 story, to this point, is split into two chapters. Amid expectations for rising interest rates, which came to pass, rate-sensitive real estate ETFs and mutual funds slumped in the first several months of 2018.
Savvy dividend investors know that international markets can provide much needed boosts to current income and portfolio yield. Scores of non-US markets, both developed and emerging, sport dividend yields in excess of the S&P 500.7 Stocks to Buy That Lost 10% in April
Incorporated in Delaware, Arrowhead Pharmaceuticals (ARWR) is focused on developing medicines for treating intractable diseases by silencing the genes that cause them. The therapies developed by Arrowhead make use of a broad portfolio of RNA chemistries and efficient modes of delivery to trigger an RNA interference mechanism that induces the rapid and durable knockdown of the target genes. RNA interference or (RNAi) is a mechanism that inhibits the expression of a specific gene.
The Federal Reserve hiked interest rates three times last year and more rate increases are expected this year. Still, 10-year Treasuries yield less than 2.7%, underscoring a nearly four-decade downtrend in U.S. borrowing costs. For its part, the S&P 500 yields an anemic 1.8%.